Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) sees significant drop in short-term interest

0

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) benefited from a sharp fall in short-term interest rates in April. As of April 30, there was short interest totaling 723,800 shares, down 31.1% from the April 15 total of 1,050,000 shares. Based on an average trading volume of 524,900 shares, the short-term interest rate ratio is currently 1.4 days.

Several equity analysts have published reports on FMS shares. Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to an “underperform” rating and lowered its share price target from $32.40 to $30.30 in a research report from Friday, February 11. Oddo Bhf upgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “outperforming” rating and set a target price of €72.00 ($75.79) on the stock in a report research on Tuesday, March 1. JPMorgan Chase & Co. raised its price target on Fresenius Medical Care AG & Co. KGaA from €48.70 ($51.26) to €51.00 ($53.68) and assigned the stock a “underweight” rating in a Thursday, May 5, research report. StockNews.com began covering Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, May 10. They set a “buy” rating on the stock. Finally, Societe Generale lowered its price target on Fresenius Medical Care AG & Co. KGaA from €61.00 ($64.21) to €57.00 ($60.00) in a Friday, February 25 research report. . Two analysts gave the stock a sell rating, seven gave the company a hold rating and four gave the company a buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $51.63.

(A d)

Experts expect the global lithium market to grow by 500% due to the explosion of electric vehicles and green energy. And a small-cap company has just taken over a large lithium deposit in a renowned location in South America.

Several hedge funds have recently increased or reduced their stakes in the company. Pzena Investment Management LLC increased its equity stake in Fresenius Medical Care AG & Co. KGaA by 22.4% during the 1st quarter. Pzena Investment Management LLC now owns 11,577,632 shares of the company worth $389,935,000 after purchasing an additional 2,118,186 shares in the last quarter. First Trust Advisors LP increased its stake in Fresenius Medical Care AG & Co. KGaA by 15.1% in Q4. First Trust Advisors LP now owns 1,925,326 shares of the company valued at $62,496,000 after purchasing an additional 252,768 shares in the last quarter. Cambiar Investors LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 18.3% in the 1st quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company valued at $45,935,000 after purchasing an additional 210,819 shares last quarter. Goldman Sachs Group Inc. increased its stake in Fresenius Medical Care AG & Co. KGaA by 2.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 514,568 shares of the company valued at $16,703,000 after purchasing an additional 14,491 shares last quarter. Finally, Invesco Ltd. increased its stake in Fresenius Medical Care AG & Co. KGaA by 54.0% in the 4th quarter. Invesco Ltd. now owns 376,173 shares of the company valued at $12,211,000 after purchasing an additional 131,870 shares last quarter. Institutional investors and hedge funds own 4.73% of the company’s shares.

Shares of Fresenius Medical Care AG & Co. KGaA were up $0.41 during Friday trading hours, hitting $29.21. 486,000 shares of the company were traded, against an average volume of 409,242. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $28.75 and a 52-week high of $42.45. The company has a market cap of $17.12 billion, a price-to-earnings ratio of 16.69, a growth price-to-earnings ratio of 1.18, and a beta of 1.17. The company has a fifty-day moving average of $32.46 and a 200-day moving average of $32.47. The company has a current ratio of 1.26, a quick ratio of 0.93 and a debt ratio of 0.51.

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) last released its quarterly results on Wednesday, May 4. The company reported earnings per share of $0.38 for the quarter, beating analyst consensus estimates of $0.30 by $0.08. Fresenius Medical Care AG & Co. KGaA achieved a return on equity of 6.99% and a net margin of 4.91%. The company posted revenue of $5.10 billion for the quarter, versus analyst estimates of $4.97 billion. On average, equity research analysts expect Fresenius Medical Care AG & Co. KGaA to post earnings per share of 1.99 for the current fiscal year.

The company also recently announced an annual dividend, which will be paid on Friday, May 27. Shareholders of record on Monday, May 16 will receive a dividend of $0.7093 per share. The ex-dividend date is Friday, May 13. This represents a dividend yield of 3.4%. The payout ratio of Fresenius Medical Care AG & Co. KGaA is 32.57%.

About Fresenius Medical Care AG & Co. KGaA (Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Read more

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Fresenius Medical Care AG & Co. KGaA right now?

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes a turn… and Fresenius Medical Care AG & Co. KGaA was not on the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Share.

Comments are closed.